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Abstract
Background: Many studies have been conducted in an extensive effort to identify alterations in blood cholinesterase levels
as a consequence of disease, including the analysis of acetylcholinesterase (AChE) in plasma. Conventional assays using
selective cholinesterase inhibitors have not been particularly successful as excess amounts of butyrylcholinesterase (BuChE)
pose a major problem.
Principal Findings: Here we have estimated the levels of AChE activity in human plasma by first immunoprecipitating
BuChE and measuring AChE activity in the immunodepleted plasma. Human plasma AChE activity levels were ,20 nmol/
min/mL, about 160 times lower than BuChE. The majority of AChE species are the light G1+G2 forms and not G4 tetramers.
The levels and pattern of the molecular forms are similar to that observed in individuals with silent BuChE. We have also
compared plasma AChE with the enzyme pattern obtained from human liver, red blood cells, cerebrospinal fluid (CSF) and
brain, by sedimentation analysis, Western blotting and lectin-binding analysis. Finally, a selective increase of AChE activity
was detected in plasma from Alzheimer’s disease (AD) patients compared to age and gender-matched controls. This
increase correlates with an increase in the G1+G2 forms, the subset of AChE species which are increased in Alzheimer’s brain.
Western blot analysis demonstrated that a 78 kDa immunoreactive AChE protein band was also increased in Alzheimer’s
plasma, attributed in part to AChE-T subunits common in brain and CSF.
Conclusion: Plasma AChE might have potential as an indicator of disease progress and prognosis in AD and warrants further
investigation.
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Introduction
Alzheimer’s disease (AD) is the leading cause of dementia in the
aged population. The main neuropathological changes associated
with AD are b-amyloid plaque accumulation, neurofibrillary
tangle formation and substantial synaptic and neuronal loss in
critical brain areas. In particular, there is good evidence of
cholinergic dysfunction in the AD brain. Acetylcholinesterase (EC
3.1.1.7; AChE), the enzyme chiefly responsible for the inactivation
of cholinergic neurotransmission, is consistently decreased in the
AD brain [1,2]. Despite this overall decrease, levels of AChE are
increased around b-amyloid plaques [3,4] and it has been
proposed that AChE may play a role in b-amyloid fibrillogenesis
[5,6]. In this context, the altered expression pattern of AChE
species in the AD brain is also of particular interest. AChE exhibits
a complex structural polymorphism depending upon its different
cellular distribution, whose significance is highly intriguing [7].
The different molecular forms of AChE are altered in AD, with a
decrease in the major AChE tetramers (G4) - probably the
cholinergic species - and subtle increase in minor light forms
(dimers, G2, and monomers, G1) [8,9]. Interestingly, the activity of
the light forms appears to increase in the most severely affected
cases [10].
While the level of AChE and its molecular species are altered in
the AD brain, AChE activity in the cerebrospinal fluid (CSF) has
also been measured in assessing the pathophysiology of AD. The
emerging consensus is that total CSF-AChE levels decrease
modestly as dementia progresses. The proportion of G1 is
enriched, but the changes are not specific for early diagnostic
and prognostic utility [11–14]. Nonetheless, measurement of
AChE levels in AD might have some value in monitoring disease
progression and is still of interest due to increasing evidence linking
b-amyloid processing and AChE activity.
Although the CSF is a more relevant source to examine
diagnostic markers for AD, plasma offers a distinct advantage as it
is more easily accessible for clinical use in monitoring disease
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have assessed plasma AChE as a marker for AD, with limited
success and reliability [15–19]. A major disadvantage encountered
is that human plasma is rich in a second enzyme capable of
hydrolysing acetylcholine - butyrylcholinesterase (EC 3.1.1.8;
BuChE), while only a minor amount of AChE is present [20].
As a result many previous and current reports on AChE activity in
plasma in several neurological and neuropsychiatric disorders have
over-estimated plasma AChE levels due to the cross catalytic
activity of BuChE. Attempts to evaluate plasma AChE by
immunoassay [21–24] have used antibodies raised against only
the major AChE forms from brain or erythrocytes and do not
react with all AChE species [25–28]. In particular, the antibodies
display low affinity for monomers [14,29,30]. As a result, levels of
plasma AChE are often under-estimated when measured by
immunoassay. Although extensive studies have been conducted in
the last three decades, a suitable assay to measure plasma AChE
levels is still lacking.
In this study, we have measured AChE activity in human
plasma, eliminating BuChE interference by prior BuChE-
immunoprecipitation. We have compared AChE activity levels
and molecular forms in normal control subjects to the levels from
human BuChE silent individuals. We have compared the different
molecular forms and subunit banding pattern of AChE by SDS-
PAGE under reducing conditions followed by Western blotting
using different anti-AChE antibodies, and glycoform patterns by
lectin-binding analysis. Plasma AChE has been compared to
AChE from human liver, red blood cells (RBCs), CSF and brain.
Finally, we have investigated whether AChE levels are altered in
the plasma of AD patients compared to normal age-matched
individuals.
Methods
Human Samples and Tissue Preparation
This study was approved by local ethics committees and was
carried out in accordance with the Declaration of Helsinki. Plasma
samples were collected in heparinized tubes at the Hospital
General Universitario de Elche (Spain) and separated from whole
blood by centrifugation at 30006g for 15 min at 4uC, aliquoted
and frozen at 280uC until use.
Patients with probable AD [11 females/3 males, 7762 yrs
(mean6 SE)] had to fulfill the criteria for the clinical diagnosis of
probable AD established by the Working Group of the National
Institute of Neurological and Communicative Disorders and
Stroke (NINCDS) and the Alzheimer’s Disease and Related
Disorders Association (ADRDA) [31]. None of the cases selected
had previously received cholinesterase inhibitor treatment. The
disease duration was 2764 months, and the severity of dementia,
evaluated using Mini-Mental State examination [32], was 1961.
For the non demented control (ND) group, age and gender-matched
healthy volunteers [12 females/3 males, 7661y r s( m e a n6 SE)]
without history, symptoms or signs of psychiatric or neurological
disease were enrolled.
Serum samples were also collected from three healthy BuChE
silent subjects (males) from the Vysya community in India (3065
years). The frequency of homozygous silent BuChE (a substitution
of leucine 307 by proline) in the Vysya community is 1 in 24, a
value 4000-fold higher than the frequency of homozygous silent
BuChE in European and American populations [33]. These
individuals are completely deficient in BuChE but have only
minor abnormalities in clinical test results [34,35].
For the initial characterization of AChE from plasma and red
blood cells, samples from healthy subjects [3 females/3 males,
4664 yrs] were employed. Red blood cells (RBCs), separated from
plasma by centrifugation, were washed three times with 154 mM
NaCl, 5.4 mM EDTA, 5 mM phosphate buffer, pH 7.5, lysed by
suspension in 20 volumes of 5 mM phosphate buffer, pH 7.5, and
membranes collected for AChE extraction by centrifugation at
10,0006g for 30 min at 4uC. CSF was collected from non-
demented controls at the Hospital Universitario San Carlos in
Madrid (obtained by lumbar puncture, 4 females/2 males,
6865 yrs). Samples containing more than 500 erythrocytes per
microliter were excluded. CSF was centrifuged at 2,0006g for
10 min to eliminate insoluble material and then stored at 280uC
for later biochemical analysis. Brain samples, small pieces of
human prefrontal cortex (,0.2 g), corresponding to cases (3
females/3 males, 6365 yrs) with no cognitive impairment, no
symptoms of any neurodegenerative disease or inflammatory brain
disease and not in any acute phases of stroke, were obtained from
Banc de Teixits Neurolo `gics, Universitat de Barcelona-Hospital
Clı ´nic (Barcelona, Spain). Fragments (,0.2 g) of normal liver
adjacent to colon cancer metastasis (2 females/4 males, 6567 yrs)
were also obtained from the Hospital Clı ´nic of Barcelona. All
tissue samples were stored at 280uC until use.
Tissue Homogenization and AChE Extraction
For AChE extraction, small pieces of frontal cortex or liver
stored at 280uC were thawed slowly at 4uC and homogenized
(10% w/v) in ice-cold Tris-saline buffer (50 mM Tris-HCl, 1 M
NaCl, and 50 mM MgCl2, pH 7.4) containing 1% (w/v) Triton
X-100 and supplemented with a cocktail of proteinase inhibitors.
The suspension was then centrifuged at 100,0006g for 1 hr at 4uC
to recover a cholinesterase rich fraction.
Membrane-bound AChE from RBCs was extracted from fresh
membrane pellets with 1 M NaCl, 50 mM MgCl2, 1% (w/v)
Triton X-100 in 15 mM HEPES, pH 7.0 (same volume as the
original blood sample, ,5 mL), supplemented with a cocktail of
proteinase inhibitors. After a 2 hr incubation at 4uC, the AChE
rich fraction was collected by centrifugation at 100,0006g for 1 hr
at 4uC.
Enzyme Assays and Protein Determination
AChE and BuChE activity were determined by a modified
microassay method of Ellman (1961). AChE was assayed with
1 mM acetylthiocholine and 50 mM tetraisopropyl pyrophosphor-
amide (Iso OMPA), a specific inhibitor of BuChE; while BuChE
was measured with 1mM butyrylthiocholine and 10mM
BW284c51, a specific inhibitor of AChE. One milliunit (mU) of
AChE or BuChE activity was defined as the number of nmoles of
acetylthiocholine or butyrylthiocholine hydrolysed per min at
22uC. Protein concentrations were determined using the bicinch-
oninic acid method, with bovine serum albumin as standard
(Pierce, Rockford, IL).
BuChE Immunodepletion
In plasma and liver samples, BuChE was first immunoprecip-
itated using an anti-BuChE polyclonal antibody (a generous gift
from Prof Oksana Lockridge, University of Nebraska Medical
Center, Omaha, NE, USA). Protein A-Sepharose (200 mL of resin)
was blocked for 2 hr with 2% bovine serum albumin in PBS and
then incubated overnight at 4uC in PBS with 10 mL of rabbit
serum containing anti-BuChE antibody. The anti-BuChE affinity
resin was incubated with plasma or liver samples (400 mL diluted
1:3 in PBS) for 8 hr at 4uC, then centrifuged at 5006g and the
supernatant fraction was re-incubated with fresh anti-BuChE
affinity resin overnight at 4uC. Immunocomplexes were separated
by centrifugation and AChE activity was determined in the
AChE in AD Plasma
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BuChE resin ensured that most of the BuChE activity in the
samples was removed. Bound and unbound fractions were also
examined by Western blotting with the anti-AChE antibody N-19
(Santa Cruz Biotechnology, Santa Cruz, CA).
Immunoprecipitation of AChE and Binding to Affinity
Matrix
Plasma samples immunodepleted of BuChE were incubated
with the anti-human AChE antibody MA3-042 (clone HR2; ABR-
Affinity BioReagents, Golden, CO) to immunoprecipitate AChE.
The resultant plasma AChE was then incubated with an affinity
matrix consisting of immobilized fasciculin-2 (Fas2-Sepharose;
Fas2 from Latoxan, Valance, France), a polypeptide toxin from
snake venom that binds with high affinity to the peripheral anionic
sites of AChE [36]. Fas2-Sepharose was prepared as described
previously [30], and the binding of plasma AChE to the affinity
matrix was tested by incubation overnight at 4uC. Bound proteins
were washed and reserved with the unbound fraction for Western
blot analysis.
Sedimentation Analysis
Molecular forms of AChE were separated according to their
sedimentation coefficients by centrifugation on 5–20% (w/v)
sucrose gradients containing 0.5% (w/v) Triton X-100. Ultra-
centifugation was performed at 150,0006g in a SW 41Ti
Beckman rotor for 18 hr, at 4uC. Approximately 40 fractions
were collected from the bottom of each tube and assayed for
cholinesterase activities. We defined the ratio of AChE forms G4/
(G1+G2) as the proportion of G4 molecules versus the sum of the
light forms, G1 and G2. The sucrose fractions containing G4 and
G1+G2 peaks were separately pooled, dialyzed against Tris buffer,
and concentrated by ultrafiltration (Amicon Ultra 10,000
MWCO, Millipore Corporation, Bedford, MA). AChE species
were then assayed by Western blotting and lectin-binding
analysis.
Detection of AChE by Western Blotting
AChE subunits in the different samples were detected by
immunoblotting. As plasma samples contain a high amount of
certain plasma proteins (albumin, immunoglobulins, transferrin
etc.), these proteins were depleted using immunoaffinity-based
chromatography (SepproH IgY14 spin column kit, GenWay
Biotech Inc, San Diego, CA) prior to electrophoresis. Samples of
plasma (25 mg of protein after protein depletion), liver (50 mg),
RBCs (50 mg), frontal cortex (40 mg) and CSF (30 ml) were resolved
by electrophoresis on 10% SDS-polyacrylamide slab gels.
Following electrophoresis, proteins were blotted onto nitrocellulose
membranes, blocked with 5% bovine serum albumin and
incubated overnight with different anti-AChE antibodies - N-19
(Santa Cruz Biotechnology), Ab31276 (Abcam, Cambridge, UK),
and an antibody raised to the unique C-terminus of human AChE-
R [37] (a generous gift from Prof Hermona Soreq, The Institute of
Life Sciences, The Hebrew university of Jerusalem, Jerusalem,
Israel). The strips were incubated with HRP-conjugated secondary
antibodies (Santa Cruz Biotechnology) and immunoreactive
AChE was detected using the ECL-Plus kit (Amersham Life
Science, Arlington Heights, IL) in a Luminescent Image Analyzer
LAS-1000 Plus (FUJIFILM). Molecular weight markers were used
to determine protein size (Sigma-Aldrich Co, St Louis, MO). For
semi-quantitative analysis, the intensity of AChE bands was
measured with the Science Lab Image Gauge v4.0 software
provided by FUJIFILM.
Lectin-Binding Analysis of AChE
Aliquots of plasma and extracts from liver (after BuChE
immunoprecipitation), RBCs, total extract from brain frontal
cortex and CSF or its enriched G4 and G1+G2 peaks were mixed
with immobilized lectins [Canavalia ensiformis (Con A) or Lens
culinaris agglutinin (LCA), both from Sigma-Aldrich Co]. After an
overnight incubation at 4uC, AChE-lectin complexes were
separated from free AChE by centrifugation at 10006g for
15 min at 4uC. The unbound AChE activity in the supernatant
fraction was used to compare differences in lectin binding among
groups.
Statistical Analysis
Measurements are expressed as means 6 SEM. Data was
analyzed by Student’s t-test or by the Bonferroni test when group
means were being compared, using SigmaStat (Version 2.03; SPSS
Inc.) software. Statistical significance was designated as p,0.05.
Results
As the elevated levels of BuChE in human plasma were
expected to interfere in the determination of AChE, two cycles of
BuChE immunoprecipitation were first performed in plasma
aliquots from healthy individuals (4664 years). Such immunopre-
cipitation reduced the levels of BuChE ,190 times, from
32426286 to 1763 mU/mL (Fig 1A). We have utilized a
polyclonal antibody raised against highly purified human plasma
BuChE that has previously been demonstrated to be effective in
immunoprecipitating human BuChE [38]. Western blot analysis
with the anti-AChE antibody N-19 confirmed the specificity of the
immunoprecipitation, with no AChE immunoreactivity detected
in BuChE immunoprecipitates (Fig 1B). The remaining AChE
activity in the BuChE depleted supernatant was 2061 mU/mL,
much lower than the levels measured before BuChE depletion
(Fig 1A).
Both cholinesterases, AChE and BuChE, are expressed as
several molecular forms that can be distinguished by their
molecular weights and hydrodynamic properties [7]. Plasma
supernatants before and after BuChE immunoprecipitation were
fractionated on sucrose density gradients to separate the different
AChE molecular forms. The G1+G2 species represented the major
peak of AChE activity in the plasma supernatants with only a
minor contribution of the G4 form after BuChE depletion (Fig 1C).
In unprocessed plasma, a major peak observed at the peak of G4
AChE, is predominantly the undepleted BuChE activity. This
tetrameric peak was significantly reduced after BuChE immuno-
depletion confirming our observation (Fig 1C). BuChE immuno-
precipitation was similarly effective in depleting both major
BuChE tetramers and light species (Fig 1D).
We further analyzed the complex AChE banding pattern in an
attempt to assign immunopositive AChE bands to specific AChE
species and to assess whether the remaining G4 peak corresponded
only to AChE. Prior to electrophoretic analysis, plasma proteins
were depleted by immunoaffinity-based protein subtraction
chromatography, as described below. Peaks G4 and G1+G2 from
the plasma supernatants fractionated on sucrose density gradients
were analyzed by immunoblotting using the anti-AChE antibody
N-19 (Fig 1E). This polyclonal antibody was raised against a
peptide mapping to the amino terminus of AChE, common to all
AChE forms and thus presumably detects all species, including
inactive subunits [30]. N-19 detected three major bands of
approximately 78, 66 and 55 kDa (Fig 1E). Immunoblotting of the
concentrated G4 gradient peak demonstrates the presence of
tetrameric AChE in the plasma with major 66 and 55kDa bands
AChE in AD Plasma
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the G1+G2 peaks showed all three AChE bands, similar to that
observed in total plasma samples (Fig 1E).
The G1+G2 forms, which are abundant in plasma, display low
binding affinity for several anti-AChE antibodies [14,29,30], and
inactive AChE molecules have been described as lighter AChE
molecules [39–41]. We have performed AChE immunoprecipi-
tation with the HR2 antibody and analyzed its pattern of binding.
The percentage of AChE not bound to HR2 was 1562% of total
plasma AChE activity. However, when immunoblotted with the
N-19 antibody, only the 66 and 55 kDa bands were identified in
the bound fraction, while the unbound fraction displayed the
three typical AChE bands (Fig 1 F). Similarly, when Fas2 affinity
matrix bound protein fraction was analyzed, 66 and 55 kDa
bands were identified, with only a faint 78 kDa band; while
unbound fractions displayed most of the 78 kDa immunoreac-
tivity (Fig 1 F). The results are in accordance with previous
observations in human CSF [30], where a considerable amount
of the AChE immunoreactivity (in particular the 78 KDa band)
detected by the N-19 antibody was associated with protein that
bound poorly to HR2 and to the allosteric AChE inhibitor Fas2.
The identity of the 78 kDa band as an AChE subunit was
assessed by re-testing our samples with another anti-AChE
antibody, ab31276 (see below).
BuChE activity is completely absent in individuals with genetic
mutations resulting in a silent phenotype of BuChE (silent BuChE)
[42]. These otherwise healthy individuals are a good archetype to
study serum AChE activity without interference from BuChE.
AChE levels in these individuals varied between 26.7, 25.0 and
21.1 mU/mL, similar to levels found in plasma from normal
healthy individuals after BuChE immunoprecipitation (Fig 1A).
Sedimentation analysis confirmed that most of the activity
corresponded to the G2 and G1 forms, while tetramers were the
minor species (Fig 1C).
Figure 1. Plasma AChE levels in healthy controls (wild-type) after BuChE immunodepletion and in BuChE-silent individuals. (A)
Control plasma was immunoprecipitated with anti-BuChE antibody and cholinesterase activity levels determined before
b and after
a
immunoprecipitation (n=6; 4664 yrs). AChE activity level in plasma from BuChE-silent individuals is also shown (n=3; 3065 yrs). The anti-BuChE
antibody does not immunoprecipitate AChE in BuChE-silent plasma (not shown). Values are means 6 SEM. (B) Immunoprecipitation of control
plasma with antibody, followed by immunoblotting with the anti-AChE antibody, N-19. The presence (+) or absence (2) of the anti-BuChE antibody
linked to the resin is indicated in the top margin. Prior to electrophoretic analysis, proteins abundant in plasma were depleted by immunoaffinity-
based protein subtraction chromatography with IgY microbeads (Seppro
TM). The anti-BuChE antibody does not immunoprecipitate AChE. Extracts
incubated with protein A-Sepharose, in the absence of the antibody, were analyzed in parallel as negative controls. (C) Representative profiles of
AChE and (D) BuChE molecular forms (G4=tetramers; G1+G2=monomers and dimers) in control plasma samples before (N) and after (#) BuChE-
immunoprecipitation, and in BuChE-silent plasma (m). (E) Representative immunoblot of individual AChE G4 and G1+G2 peak-fractions separated by
sucrose gradient centrifugation from control plasma and detected with the N-19 antibody (a similar volume for both the G4 and G1+G2 peaks was
loaded in each lane). (F) Comparison of the AChE-banding pattern detected with the N-19 antibody, for fractions bound and unbound to the anti-
AChE antibody HR2 and to the Fas2-Sepharose affinity matrix.
doi:10.1371/journal.pone.0008701.g001
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We performed a comparative analysis of AChE from different
human tissues and fluids obtained from non-diseased subjects. The
different AChE molecular species are cell type-dependent, with
differences in developmental and adult tissues and in different
species [7]. As the molecular pattern of AChE in human tissues is
unclear, we have analyzed the different molecular forms of AChE
in liver, RBCs, CSF and brain extracts and compared these to the
pattern obtained from plasma which is rich in light species and
contains only trace amounts of tetramers (Fig 2A). Sedimentation
analysis of AChE from liver (total AChE activity levels,
2.260.3 mU/mg) and RBC extracts (491640 mU/mg) showed
similar profiles to that of plasma, whereas CSF (1662 mU/mL)
and frontal cortical extracts (1062 mU/mg) displayed abundant
amounts of G4 and small amounts of the G1+G2 species.
Different cell types have been demonstrated to add different
carbohydrate moieties onto AChE [43]. In order to gain further
insight into the origin of plasma AChE, we have studied the ability
of the plasma enzyme to bind to the lectins Canavalia ensiformis
(Con A) and Lens culinaris agglutinin (LCA) in comparison to
AChE from liver, RBCs, CSF and brain. Con A binds specifically
to mannose groups, while LCA interacts with a-mannosyl residues
of N-linked sugar chains, but also requires the presence of a fucose
residue bound to the C-6 hydroxyl group of the GlcNAc at the
reducing end of glycoprotein, for strong binding. Since different
molecular forms of AChE have different glycosylation patterns
[9,44], lectin-binding analysis was performed on total extracts
from enriched CSF and the G1+G2 peaks from brain obtained
after sucrose density gradients, focussing on the light forms to
compare with the plasma AChE forms (Fig 2A). Similar results
Figure 2. AChE molecular form and lectin-binding profile in human plasma, liver, RBCs, CSF and brain (frontal cortex). (A)
Representative profiles of AChE molecular forms (G4=tetramers; G1+G2=monomers and dimers). (B) Comparison of Con A and LCA binding of AChE.
Plasma, CSF and total extracts from liver, RBCs and brain (n=6 for each group) were incubated with immobilized lectins, AChE activity was assayed in
the supernatants and the percentage of (%) AChE activity unbound to lectins was calculated. For total CSF and brain extracts, both rich in tetramers,
the % AChE unbound to Con A (%Unb Con ACSF=361; %Unb Con ABrain=461) and to LCA (%Unb LCACSF=461; %Unb LCABrain=1762) were
determined. Additionally, individual G4 and G1+G2 fractions, separated by sucrose gradient centrifugation, from CSF and brain extracts (n=5), were
also pooled, dialyzed against Tris-saline-Triton X-100 buffer, and concentrated by ultrafiltration. AChE peaks were then assayed by incubation with
immobilized lectins, and the percentages of unbound enzymatic activity were calculated. For CSF tetramers, the %Unb Con A was 0.960.5; and the
%Unb LCA was 0.360.1. For brain tetramers, the %Unb Con A was 1.360.2; and the %Unb LCA 2.460.2. Please note differences in lectin binding for
total AChE from brain or CSF, or its enriched G4 fractions, when compared to the respective G1+G2 peaks (see Figure), revealing distinct glycosylation
patterns for different AChE molecules. Values are means6 SEM *p,0.05, significantly different from plasma samples, as assessed by one-way analysis
of variance with Bonferroni posttest.
doi:10.1371/journal.pone.0008701.g002
AChE in AD Plasma
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8701were obtained between plasma and liver extracts for the
percentage of AChE unbound to Con A. In contrast, a difference
in Con A binding was observed between plasma AChE and the
G1+G2 peaks from brain or CSF. The major difference was seen
with RBCs where the enzyme from these cells was only poorly
recognized by the lectin (Fig 2B). However, a similar interaction
with LCA was seen for the AChE from plasma, brain G1+G2, and
RBCs (Fig 2B). The enzyme in plasma does not reproduce the
binding pattern of a single tissue, probably due to the diverse
number of cellular origins.
Finally, some of the molecular heterogeneity of AChE is also
derived from alternative RNA splicing, generating different
polypeptide encoding transcripts (called ‘‘tailed’’ or T, ‘‘hydro-
phobic’’ or H and ‘‘readthrough’’ or R-transcripts) with the same
catalytic domain, and distinct C-terminal peptides that determine
the ability of the molecule to form oligomers [7,45]. All transcripts
are able to generate AChE monomers, therefore the resultant
AChE monomeric variants cannot be distinguished by molecular
weight. Thus, we further characterized the complex subunit
banding-pattern obtained by SDS-PAGE/Western blotting using
different anti-AChE antibodies (Fig 3). As stated above, the
antibody N-19 (Fig 3A) raised against a peptide that maps the N-
terminus of human AChE, common to all variants, detected the
three major bands of approximately 78, 66 and 55 kDa in
immunoblots from plasma samples, similar to those from CSF,
while brain extracts display a more complex banding pattern with
more than 3 bands observed. Immunoblots performed for the
G1+G2 peaks from sucrose density gradients reproduce all the
major AChE bands, as observed in total extracts. In liver extracts
the 55 kDa band is the only clearly defined band with faint
staining for the other heavier subunits. In contrast, blots from
RBC extracts showed only a 78 kDa band. In addition to N-19, we
used another anti-AChE antibody, ab31276 (Fig 3B), which
recognizes residues 601–614 at the C-terminal of human AChE-T.
A similar pattern of AChE labelling with N-19 and ab31276
antibodies was also demonstrated for plasma, CSF, brain and liver
extracts, indicating that most of the AChE immunoreactivity
consists of T-subunits. The rabbit anti-human antibody to AChE-
R (Fig 3C) is directed to the unique C-terminus of AChE-R [37].
This antibody detected a 55 kDa band in blots of plasma, liver,
CSF and brain indicating the presence of R-subunits; however, T-
subunits of this size are also probably present. No band was
resolved for the RBC extract with antibodies to AChE-T or R, in
accordance with its glycophosphatidylinositol membrane anchor
at the C-terminus (Fig 3B, C).
The level of plasma AChE in BuChE immunodepleted samples
obtained from AD patients were screened for activity. The AChE
assay revealed that AD-plasma samples had higher activity, (20%
increase; p=0.01), in comparison to age and gender-matched
controls, while no change was found in BuChE levels (Fig 4A). To
determine if the AChE molecular pattern is altered in AD plasma,
the supernatants of BuChE immunoprecipitated samples were
fractionated on sucrose density gradients. In AD plasma, a slight
decrease was observed in the minor G4 peak, and an increase in
the G1+G2 species, resulting in a significant decrease in the G4/
(G1+G2) ratio (p=0.006) (Fig 4B). The BuChE levels and G4/
(G2+G1) ratio of the AD group were indistinguishable from the
control group (Fig 4B).
The AD plasma samples were also subject to SDS-PAGE
under fully reducing conditions, followed by Western blotting
using the anti-AChE antibody N-19. The abundant plasma
proteins were depleted as previously described and equivalent
amounts of protein were loaded for each sample. N-19 detected
the three major bands of 78, 66 and 55 kDa in plasma samples
from both AD and control subjects (Fig 5A). Interestingly, the
78-kDa subunit was significantly increased (62%, p=0.02) in
AD samples (Fig 5A–B). The large increase in immunoreactivity
in comparison with AChE activity may be attributable in part to
the partially inactive or subnormally active character of this
subunit (Fig 1E). This trend in the increase in immunoreactivity
Figure 3. Immunodetection of AChE subunit variants in human plasma, liver, RBCs, CSF and brain (frontal cortex). Samples were
immunoblotted with three anti-AChE antibodies, (A) the N-terminal N-19, which recognizes all variants; (B) the C-terminal ab31276, which recognizes
only AChE-T subunits; and (C) the anti- AChE-R antibody directed at the unique C-terminus of AChE-R. Representative immunoblot with the N-19
antibody of individual G1+G2 peak fractions separated by sucrose gradient centrifugation from CSF and brain are included (A, right panel).
doi:10.1371/journal.pone.0008701.g003
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ab31276 antibody (Fig 5C). The levels of other immunoreactive
AChE bands were not significantly different in AD plasma
(Fig 5B).
Discussion
There have been an extensive number of investigations in efforts
to identify alteration in blood cholinesterase levels as a
consequence of disease processes. The status of red blood cell
AChE and plasma BuChE are considered important indicators for
the treatment of patients affected in several pathologies and in
poisoning by organophosphorus compounds; some studies extend
this analysis to include plasma AChE. Routinely, when both
AChE and BuChE activities are estimated independently within
the same extract, an adaptation of the Ellman method (1961) is
employed using specific substrates and inhibitors. When measured
by this method, plasma BuChE/AChE ratios differ greatly in
mammals. Rat or rabbit plasma is reported to have less BuChE
than AChE activity (BuChE/AChE, 0.5–0.7), while mouse or
guinea pig plasma has more BuChE than AChE activity (BuChE/
AChE, 5–8) (see [46] for a review). In these particular situations,
conventional independent measurement of both cholinesterases
using specific inhibitors and substrates is reasonably reliable.
However, several immuno-chemical studies have indicated that
BuChE levels in human plasma are in substantial excess to AChE
[21–24]. Presently, it is extremely difficult to determine human
plasma AChE levels by the use of BuChE inhibitors, as BuChE is
presented in much large amounts than AChE. Results of classical
spectrophotometric studies of AChE in AD serum or of the
enzyme in plasma have been contradictory and vary widely in
activity from very low values (6–12 mU/mL), similar to values
reported from immunoassays [15,16,47], to 10–50 times higher
(60–300 mU/mL) [17,18], to values similar to that observed for
BuChE (,2000 mU/mL) [19,48]. These large differences are
probably due to the use of a diverse concentration of BuChE
inhibitors, protocols simultaneously using both competitive AChE
and BuChE inhibitors, and the presence of detergents in the
plasma dilution buffer (BuChE is highly sensitive to inhibition by
detergents; see ref [46,49]). These inconsistencies are applicable to
many previous and current reports of AChE activity in different
pathological conditions, and elevated plasma levels of AChE (as
high as levels of BuChE) are commonly reported. Previous studies
(all from the same group [15,16,47]) performed with a conven-
tional Ellman’s method have reported plasma AChE activity levels
in the range observed in our present study. Interestingly, Atack
Figure 4. AChE levels and molecular form pattern are altered in plasma samples from non-demented controls (ND) and Alzheimer’s
patients (AD). (A) Box plot comparing total plasma-AChE activity from 15 ND and 14 AD cases, AChE activity was calculated after BuChE depletion.
AChE molecular forms were separated, identified by sedimentation analysis (representative profiles; left panel), and a G4/(G1+G2) ratio calculated
(n=6 for each group). * p,0.05 significantly different from NDs, as assessed by Student’s t-test. (B) Total BuChE and molecular form pattern was also
calculated, prior to immunoprecipitation, with no statistically significant differences between groups.
doi:10.1371/journal.pone.0008701.g004
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plasma from AD subjects [15,16]. In these studies, plasma AChE
was assayed in the presence of the BuChE inhibitor iso-OMPA at
10
24 M (in our assay, 5610
25 M). Activity was also assayed in the
presence and absence of the AChE inhibitor BW284c51, and only
the activity sensitive to BW284c51 was considered to represent
AChE. Using this methodological approach, the amount of AChE
was estimated by subtraction of cholinesterase activity sensitive to
the double inhibitor from the activity sensitive to the BuChE
inhibitor; and our colleagues reported that more than half (56%) of
the plasma AChE activity was constituted by G4 tetramers [47]. In
this study, we demonstrate that after BuChE immunodepletion,
tetramers contribute a minor proportion of the total AChE activity
(see Figs 1 and 4). Thus, it is possible that the combination of
inhibitors and ‘‘subtraction’’ approach used by Atack et al does not
completely eliminate BuChE interference in the determination of
AChE levels in human plasma. As such, subtle changes in plasma
AChE levels cannot be precisely determined using conventional
assay methods.
Our ultimate aim in this study was to determine plasma AChE
levels in AD patients in comparison to normal individuals. A
prevalence of lighter AChE forms occurring in parallel with a
decrease in G4 has been observed in both brain and CSF samples
in AD [9]. We have also found that the level of a salt-extractable
amphiphilic monomeric form of AChE is increased in the brains of
transgenic mice which produce the human b-amyloid protein [50],
and in the brain and CSF of rats which received intra-
cerebroventricular injections of b-amyloid peptides [51]. So far,
the exact nature of this subset of G1 species which is increased in
the AD brain remains unclear, although this minor species can be
distinguished from other brain AChE forms (including tetramers
but also from other monomeric AChE isoforms), by its unusual
lectin-binding pattern and lack of binding to anti-AChE antibodies
[14,30]. AChE exhibits high molecular polymorphism contributed
by alternative splicing and by the presence of different carbohy-
drate moieties on the molecule. Hence, homologous AChE
isoforms from different tissues [43] differ in their glycosylation
pattern. This observation has been confirmed in the present study.
Therefore, it is not surprising that antibodies raised against native
AChE species display different affinity for distinct AChE
molecules.
In this study, we have been able to determine AChE levels in
plasma by immunoprecipitating and therefore removing BuChE.
As a result, BuChE levels in the plasma are reduced by ,190 fold,
to lower levels than AChE. Our measured human plasma AChE
levels are ,20 mU/mL, in the range of the activity levels
determined for CSF AChE. These levels are also similar to the
levels of AChE obtained in the plasma of ‘‘BuChE silent’’
individuals, which serve as useful controls for the specificity of the
immunoprecipitation process and for assessing decline in activity
due to the precipitation conditions and time of incubation.
Furthermore, the possibility of hybrid cholinesterase forms
consisting of hetero-multimers of AChE and BuChE subunits
has been proposed in normal [52] and pathological conditions
[53]. However such possibility has been excluded by western blot
analysis for AChE of the plasma BuChE immunoprecipitates,
confirming the negligible amount of AChE in such samples.
Using the present methodological approach, based on BuChE
immunoprecipitation, we have demonstrated that plasma AChE
activity levels are increased in AD patients. This increase
correlates with an increase in the light AChE species which are
the major species in human plasma, whereas tetramers, which are
normally only present in trace amounts, are slightly decreased in
AD plasma. This AChE G1+G2 peak is not a result of any BuChE
activity as only minor amounts of light BuChE species remain after
immunoprecipitation. Blots of material from the G1+G2 peak also
showed an analogous Western blotting-banding pattern in total
plasma. Monomeric AChE was seen in wild-type as well as in
silent BuChE plasma by non-denaturing gradient gel electropho-
resis [20]. As these light species are the major species in human
plasma, this low affinity may explain why previous immunoassay
studies observed lower plasma AChE levels than reported in the
Figure 5. Altered AChE immunoreactivity in plasma of non-demented controls (ND) and Alzheimer’s disease (AD) patients. (A)
Representative blot of plasma-AChE from AD and ND using the antibody N-19, and (B) densitometric quantification of the AChE-immunoreactive
bands, expressed in arbitrary units (a u.), from 15 ND (&; n=15) and 14 AD (%; n=14) subjects. Proteins abundant in plasma were depleted by
immunoaffinity-based protein subtraction chromatography with IgY microbeads (Seppro
TM) and equivalent amounts of protein were loaded in each
lane. Columns represent means 6 SEM *p=0.02 significantly different from NDs as assessed by Student’s t test. (C) Representative blot of plasma
AChE detected with the anti-AChE antibody to the C-terminal, ab31276.
doi:10.1371/journal.pone.0008701.g005
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BuChE in human plasma have been unsuccessful as the affinity
resin usually used to separate these enzymes (edrophonium-
Sepharose), binds only soluble tetramers [54], whereas soluble
light species present in plasma which have amphiphilic properties
do not bind [55]. We have estimated that only ,20% of the
human plasma AChE activity bound to an edrophonium-
Sepharose affinity matrix (not shown).
It has been generally assumed that in humans, plasma BuChE
originates in liver cells; however contributors to the plasma pool
for AChE may include other organs. As AChE is an ubiquitous
protein present in many, if not all tissues, it has been proposed that
plasma AChE might originate from several tissues, including liver,
brain, muscle and nerve, nucleated blood cells and RBCs. All of
these organs express the light AChE species which is abundant in
human plasma. As sedimentation analysis cannot distinguish
between monomeric isoforms which are synthesized in distinct cell
types, we have studied the AChE glycosylation pattern, which is
cell specific. The ability of lectins to recognize specific carbohy-
drate residues of glycoproteins, makes them excellent tools to
detect subtle differences in glycosylation patterns. We have focused
our study on the G1+G2 species, where we have separated and
enriched these peaks in CSF and brain to compare it with the liver,
RBCs and plasma, where these forms are abundant. As expected,
differences in the binding properties of AChE from liver, brain and
RBCs to lectins indicate a distinct pattern of glycosylation derived
from different cellular origins of the AChE protein. The
comparison of AChE-lectin binding profiles for the two mannose
specific lectins, LCA and Con A, give no definitive conclusion
because the enzyme in plasma does not reproduce the binding
pattern of a single tissue, probably due to the diverse number of
cellular origins.
Regulation of AChE at the transcriptional level also corresponds
to a cell specific pattern. We have analyzed the protein product of
the three different AChE transcripts, with distinct C-terminal
peptides, to obtain additional information regarding the cellular
origin of plasma AChE. We have performed Western blots and
analyzed these plasma samples with anti-AChE antibodies raised
against peptides mapping to the common N-terminal or specific C-
terminal domains of the various AChE variants. Using western
blot analysis, both active and inactive subunits of the enzyme are
detected [30,37–41,44]. Our immunoblotting assays have revealed
a complex AChE banding pattern with major AChE bands of 78,
66 and 55 kDa. The full-length AChE is predicted to be ,70 kDa
in size. Accordingly, using non-denaturing polyacrylamide gels
stained for AChE activity, molecular weights of AChE subunits are
in the range of 70–75 kDa. However, analysis by SDS-PAGE and
Western blotting by us and others, under fully reducing conditions
and with several different anti-AChE antibodies, detected bands
ranging from 75 to 50 kDa, for the AChE protein from different
sources and animal species, including humans [30,37,44,56–60].
The specificity of the 78 kDa AChE bands and of the lower
molecular weight AChE bands was confirmed by immunoprecip-
itation, Fas2 affinity matrix binding and immunodetection of blots
with different anti-human AChE antibodies (including the N-
terminal N-19 and the ab31276 antibody, which recognizes the C-
terminal residues 601–614 of human AChE-T) and is in
agreement with our previous study in human CSF [30]. The
lower molecular weight bands are not attributable to differences in
glycosylation and may originate by post-translation modification
and/or result from the reducing conditions used during electro-
phoresis. The AChE banding pattern appears specific for each
tissue and with no simple relationship to specific molecular forms
and enzymatic activity [30,44].
These data demonstrate that most of the AChE immunoreac-
tivity in the G1+G2 sucrose fractions from plasma consists of T-
subunits. Thus, in our plasma samples, we have attributed the H-
subunit to the 78 kDa band; and the 55 KDa band to R-subunits.
In addition, bands of 78 and 55 kDa are also attributed to T-
subunits as they react with the ab31276 antibody. Thus, T- and R-
subunits of these sizes are present in all tissues analyzed except
RBCs. The increased level of AChE activity in AD plasma was
also accompanied by an increase of 78-kDa subunits. We believe
that this increase of the 78 kDa subunit is due in part to AChE-T
as blots with the ab31276 antibody also demonstrate increased
immunoreactivity for this band in AD samples. Both active and
inactive subunits of the protein could contribute to the
immunoreactivity of this band. As expected, the 78-kDa band is
present in the concentrated G1+G2 peaks, but little or none was
observed in the G4 peaks. The 78 kDa T-subunit is also present in
G1+G2 peaks from liver, CSF and brain. Currently our studies can
only exclude RBCs as a potential source of the increased AChE in
AD plasma. In addition to the 39 alternatively spliced species of
AChE that generate proteins with distinct C termini, the 59 end is
also subject to intricate regulation, as recently demonstrated by
Soreq and co-workers [61], generating AChE variants that have
extended N-termini (N-AChE-T, N-AChE-R, N-AChE-H). In-
creased N-AChE expression in the AD brain has been associated
with disease progression and apoptotic cell death [62]. The
antibodies used in this study do not distinguish between
‘‘canonical’’ and N-extended variants, therefore these variants
cannot be excluded from contributing to the complex AChE
banding pattern detected in plasma.
Plasma AChE is likely to have multiple cellular origins,
including cells from the brain. Thus, we can hypothesize that
the increase observed in AD plasma may be associated with the
particular increase in the light AChE species which characterizes
the AD brain [9,10].
The transport of circulating molecules in the brain is strictly
controlled by the blood-brain barrier. Liposolubility or catalyzed
transport are the main modes of passage through the blood-brain
barrier. This barrier, offered by capillary endothelial cells of the
brain, is highly restrictive for the passage of molecules larger than
500 daltons. The blood-CSF barrier, formed by the choroid plexus
and the arachnoid membrane, is a more permeable barrier.
Intraperitoneal administration of purified human BuChE to rats
demonstrated that a hydrophilic tetrameric form of BuChE crosses
the blood-CSF barrier, resulting in less than 0.1% of the BuChE
concentration in plasma [38]. It is expected that a higher
proportion of a light and amphiphilic protein, such as G1 AChE,
will cross the blood-CSF barrier. A profound change in blood-
brain barrier permeability associated with Alzheimer’s disease
[63,64], may be facilitating the movement of AChE monomers
through CSF/brain to the blood. Thus, we can presuppose that at
least a fraction of the total increase in plasma AChE levels derives
from the brain. Further studies of the relationship between CSF/
brain and plasma AChE species are still needed.
In conclusion, this is the first study that reports levels of AChE
in human plasma without interference by BuChE. We have
demonstrated increased plasma AChE activity in subjects with
early AD. Although the current observed changes are of
insufficient magnitude to warrant the use of AChE as a reliable
diagnostic marker due to the substantial overlap between AD and
control samples, we can speculate that an assay which is capable of
discriminating between plasma AChE variants of different origins
will be useful as a potential biomarker. At present, patients
included in the study remain clinically diagnosed as probable AD
cases and no subjects are neuropathologically confirmed as definite
AChE in AD Plasma
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mortem examination, is found to be about 80–90% accurate at
best. Thus, we cannot rule out the possibility that a percentage
(10–20%) of the individuals in this group were misdiagnosed. In
addition, as the mean age of all controls was approximately 75
years, a small percentage (perhaps 5–10%) of individuals in this
group may have early preclinical AD. Therefore, the true degree
of overlap between controls and AD cases may be less than that
shown, because of the inherent uncertainty of clinical diagnosis.
The specificity and sensitivity of plasma AChE as a marker of AD
can only be accurately determined in a prospective study, when
diagnosis can be confirmed by pathology. Similarly, the effect of
long-term treatment with cholinesterase inhibitors on plasma
AChE levels should be examined.
Plasma is easily accessible in comparison to CSF, and it is
therefore important to continue the measurement of these
enzymes in demented patients as an option to CSF. If it is
possible to monitor changes in plasma AChE as a function of
disease duration and progress, this may provide a new insight into
the use of this enzyme as a diagnostic marker in the development
of AD pathology.
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